Prognostic Value of PtcO2 in Patients With COVID-19

Launched by SOUTHEAST UNIVERSITY, CHINA · Jan 10, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a special test called transcutaneous oxygen pressure (PtcO2) to see if it can help doctors predict how patients with COVID-19 might respond to treatment and their chances of recovery. The study focuses on patients who have COVID-19 and are experiencing severe breathing problems, which can sometimes lead to needing care in an intensive care unit (ICU). The trial is currently recruiting participants aged 18 to 80 who have been diagnosed with COVID-19 pneumonia and have low oxygen levels.

If you or a family member are considering participating, you'll need to meet certain criteria. For example, you should have COVID-19 pneumonia with specific imaging features, and your oxygen levels need to be below 93% while resting. However, pregnant women, those who are breastfeeding, or individuals who do not want to undergo the PtcO2 monitoring will not be eligible. Participants can expect to undergo monitoring that will help doctors gather important information about their condition, which may lead to better treatments for COVID-19 in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18-80 years, male or female; Patients with COVID-9 pneumonia (typical imaging features of COVID-19 pneumonia) (oxygen saturation ≤ 93% during air or arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg at rest)；
• Exclusion Criteria:
• • Pregnant or lactating women; Patients who refuse to undergo transcutaneous tissue oxygen pressure monitoring; Clinicians believe that patients are not appropriate; Patients undergoing ECMO.